South America Montelukast Intermediate Market

ID: MRFR/HC/51293-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026
South America Montelukast Intermediate Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria) andBy Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Pharmaceuticals
      2. 4.1.2 Research and Development
      3. 4.1.3 Chemical Manufacturing
      4. 4.1.4 Healthcare
      5. 4.1.5 Agriculture
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Allergy Treatment
      2. 4.2.2 Asthma Management
      3. 4.2.3 Respiratory Disorders
      4. 4.2.4 Chronic Obstructive Pulmonary Disease
      5. 4.2.5 Pediatric Care
    3. 4.3 Healthcare, BY Distribution Channel (USD Million)
      1. 4.3.1 Direct Sales
      2. 4.3.2 Wholesale Distribution
      3. 4.3.3 Online Retail
      4. 4.3.4 Pharmacy Chains
      5. 4.3.5 Hospital Supply
    4. 4.4 Healthcare, BY Formulation Type (USD Million)
      1. 4.4.1 Tablets
      2. 4.4.2 Oral Suspension
      3. 4.4.3 Inhalation Solutions
      4. 4.4.4 Injectables
      5. 4.4.5 Granules
    5. 4.5 Healthcare, BY Market Type (USD Million)
      1. 4.5.1 Generic Montelukast
      2. 4.5.2 Branded Montelukast
      3. 4.5.3 Intermediate Chemicals
      4. 4.5.4 Active Pharmaceutical Ingredients
      5. 4.5.5 Raw Materials
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Mylan N.V. (NL)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Sandoz International GmbH (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AstraZeneca PLC (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Hikma Pharmaceuticals PLC (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Zydus Cadila (IN)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sun Pharmaceutical Industries Ltd (IN)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Dr. Reddy's Laboratories Ltd (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY END USE
    4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
    6. 6.6 SOUTH AMERICA MARKET ANALYSIS BY MARKET TYPE
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY MARKET TYPE, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY MARKET TYPE, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
      4. 7.2.4 BY FORMULATION TYPE, 2026-2035 (USD Million)
      5. 7.2.5 BY MARKET TYPE, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America South America Montelukast Intermediate Market Segmentation

South America Montelukast Intermediate Market By Application (USD Million, 2022-2035)

  • Pharmaceuticals
  • Research and Development
  • Chemical Manufacturing
  • South America Montelukast Intermediate Market
  • Agriculture

South America Montelukast Intermediate Market By End Use (USD Million, 2022-2035)

  • Allergy Treatment
  • Asthma Management
  • Respiratory Disorders
  • Chronic Obstructive Pulmonary Disease
  • Pediatric Care

South America Montelukast Intermediate Market By Distribution Channel (USD Million, 2022-2035)

  • Direct Sales
  • Wholesale Distribution
  • Online Retail
  • Pharmacy Chains
  • Hospital Supply

South America Montelukast Intermediate Market By Formulation Type (USD Million, 2022-2035)

  • Tablets
  • Oral Suspension
  • Inhalation Solutions
  • Injectables
  • Granules

South America Montelukast Intermediate Market By Market Type (USD Million, 2022-2035)

  • Generic Montelukast
  • Branded Montelukast
  • Intermediate Chemicals
  • Active Pharmaceutical Ingredients
  • Raw Materials

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035